阿德福韦酯联合还原型谷胱甘肽治疗失代偿期乙型肝炎后肝硬化的疗效观察  

The clinical efficacy of adefovir dipivoxil combined with reduced glutathione therapy for decompensated hepatitis B cirrhosis

作　　者：向明确[1] 潘菁[1] 何茂锐[1] 杨鸿[1] 谢伶华[1] 曹永平[1] 

机构地区：[1]重庆市第九人民医院感染科,400700

出　　处：《重庆医学》2014年第9期1093-1094,1097,共3页Chongqing medicine

摘　　要：目的研究阿德福韦酯联合还原型谷胱甘肽治疗失代偿期乙型肝炎后肝硬化的临床疗效。方法将76例失代偿期乙型肝炎后肝硬化患者分成观察组与对照组,每组38例。两组均采取对症支持治疗,观察组加用阿德福韦酯联合还原型谷胱甘肽治疗。3个月后观察两组患者肝功能、临床疗效及乙型肝炎病毒DNA定量。结果观察组治疗后肝功能改善,总有效率均优于对照组(P<0.05),乙型肝炎病毒DNA转阴率显著优于对照组(P<0.01)。结论阿德福韦酯联合还原型谷胱甘肽治疗失代偿期乙型肝炎后肝硬化可有效改善肝功能,促进乙型肝炎病毒DNA转阴,控制肝硬化失代偿的并发症,疗效确切。Objective To study the clinical efficay of the therapy adefovir dipivoxil combined with reduced glutathione in the treatment of decompensated hepatitis B cirrhosis .Methods 76 cases of decompensated hepatitis B cirrhosis were divided into the treatment group and the control group ,38 cases in each group .Both groups take symptomatic and supportive treatment ,the obser-vation group plus adefovir dipivoxil combined with glutathione therapy .After 3 months treatment ,we observed liver function ,hepa-titis B virus DNA quantification and assessed the clinical efficacy .Results After treatment ,the treatment group liver function im-proved was significantly better than the control group （P＆lt;0 .05） ,the total effective rate was higher than the control group （P＆lt;0 .05） ,the rate of hepatitis B virus DNA turn to negative was significantly higher than the control group （P＆lt;0 .01） .Conclusion Adefovir dipivoxil combined with reduced glutathione therapy for decompensated hepatitis B cirrhosis can effectively improve liver function ,suppress hepatitis B virus DNA undetectable ,reduce the incidence of the complication ,and worthy of promote in our clini-cal practice .

关 键 词：谷胱甘肽 肝硬化 阿德福韦酯 

分 类 号：R575.2[医药卫生—消化系统]